Work the way you live Deloitte Shared Services Conference 2019 · Life Sciences & Healthcare...
Transcript of Work the way you live Deloitte Shared Services Conference 2019 · Life Sciences & Healthcare...
Work the way you liveDeloitte Shared Services Conference 2019
Life sciences and healthcareJohn Haughey and Candice Sieg, Deloitte
Life sciences and healthcare© 2019 Deloitte MCS Limited. All rights reserved.
John is Deloitte's Global Life Sciences Consulting leader and the Life Sciences & Healthcare industry leader for the UK.
He has extensive experience in the industry as well as more broadly cross sector, having led multiple large scale business and operational transformations over the past 30 years. He has operated across the full project lifecycle from feasibility through implementation.
John’s specialism is in optimising global business operations, covering strategy, M&A integration and divestment, operational and financial improvement, ERP implementation, global business services, analytics and outsourcing.
John Haughey Partner, Deloitte+44 20 7303 [email protected]
Candice leads the Global Business Service practice in the UK and has more than 15 years of experience in Finance, HR and Procurement transformation.
She has led a number of programmes both within industry and consulting from Shared Services feasibility through to optimisation, and maturity benchmarking.
Candice has wide industry experience in both Private and Public sectors but focusses predominantly on Life Sciences and Healthcare.
Candice SiegDirector, Deloitte+44 020 7007 [email protected]
Life sciences and healthcare© 2019 Deloitte MCS Limited. All rights reserved.
Exponential change will accelerate the pace of disruption
Life sciences and healthcare© 2019 Deloitte MCS Limited. All rights reserved.
Present 14 Years 21 Years
Pa
ce o
f In
no
va
tio
n
Perception is linear…
Reality is exponential…
7 Years
Tre
nd
s u
nd
erl
yin
g
exp
on
en
tia
l g
row
th
Nanotechnology
Quantum Computing
Robotics
Biomedical
Engineering
Artificial Intelligence
Cost of Data Storage
Connectivity
Augmented Reality
3D Printing
Understood… Directional… Unknown
Exponential change will accelerate the pace of disruption
Life sciences and healthcare© 2019 Deloitte MCS Limited. All rights reserved.
The empowered consumer is becoming increasingly focused on their wellbeing and demanding more customised products and insurance offerings
Trends driving a new Future of Health in 2040
“N of 1” personalised care
Evolution of trusted patient / caregiver relationship
From care to health to wellbeing
Interconnected health communities
Affordable health for all
Personal cognitive & AI for improved outcomes
Health data ownership by consumers
Acceleration of digital health evolution
Regulation encouraging long-term accountability
Native data-oriented entrants disrupting incumbents
Life sciences and healthcare© 2019 Deloitte MCS Limited. All rights reserved.
Power new ways to complete enabling tasks and address jobs-to-be-done in the future
Radically interoperabledata and open, secure platforms
Primarily aimed to sustain wellbeing, providing care only in the rare instances when wellbeing fails
Life sciences and healthcare© 2019 Deloitte MCS Limited. All rights reserved.
Data convener
Aggregate / store individual, population, institutional, environmental data (e.g., electronic life record). Enable
interoperability and ensure privacy/security
Science and insights engine
Conduct research and generate data insights far beyond human capabilities to aid care delivery (e.g., personalised therapy, drug
discovery, wellness coaching, clinical decision support)
Data / platform infrastructure builder
Develop and manage site-less health infrastructure (e.g., App store-like platform); set standards for platform components
Health products developer
Power the consumer health ecosystem by developing and manufacturing wellness and care products/components (e.g.,
apps, supplements, drugs, connected devices)
Consumer-centric health “virtual home + community”
Provide virtual, personalised wellness and care to consumers. Leverage community to encourage behavior change. Educate
consumers, care givers on managing wellbeing
Specialty care operator
Provide essential specialty care when in-home wellness and care fails (e.g., specialty centers for difficult cases and transplants)
Localised health hub
Serve as the local hub for education, prevention, treatment in a retail setting. Manage multi-stakeholder ecosystems and
connect to health home
Connectors and intermediaries
Run the just-in-time delivery supply chain, fulfill device and medication deliveries
Individualised financer
Offer individualised modular health coverage packages and reduce health care cost
Data + platform Wellbeing + care delivery Care enablement
Powered by radically interoperable data for a personalised and seamless consumer experience
Regulator
Define regulations to catalyse the future of health while ensuring consumer, public safety
10 winning business archetypes in the Future of Health
Life sciences and healthcare© 2019 Deloitte MCS Limited. All rights reserved.
How can GBS support the future of the Life Sciences industry?
Life sciences and healthcare© 2019 Deloitte MCS Limited. All rights reserved.
GBS leaders must act fast to stay ahead of the game and be the catalyst for disruption and change
Our point of view: life sciences organisations have traditionally led the charge on GBS
Emerging
Traditional
Cost reduction Value creation
GBS capabilities
Business objectives
Under attack nowTypical scope
Service expansion to non-traditional
functions and specialised capabilities. Shift of
focus from cost take-out to value creation
(improving cash flow, reducing risk, etc.)
Traditional GBS organisation to include
services such as Finance, HR and IT. Primary
drivers for operations are complexity
reduction and cost optimisation
Transaction processing factory
Future Of GBS
Creating an innovative set of capabilities to
maximise value via targeted digital solutions,
strategic enterprise delivery and a global
footprint
Centres of Excellence(e.g., management reporting, global
deployment)
Enterprise digital strategy office and incubator
Expanding scope (legal, regulatory affairs, social media, procurement, etc.)
Cross-functional continuous improvement taskforce
M&A SWAT Team
Predictive analytics
*Examples cited along curve are illustrative
Collaborative go-to-market strategy with GBS leading data as a revenue stream
Positively disrupting the GBS model
• GBS organisations are attracting and developing capable resources with:
− Advanced competencies in process design and data mining
− Deep knowledge of the end-customer
• Teams continue to invest in future capabilities (e.g., cloud computing, robotic process automation and predictive analytics)
• As these organisations pursue new business services, their counterparts continue to redefine expectations
Life sciences and healthcare© 2019 Deloitte MCS Limited. All rights reserved.
What does this mean for GBS in 2040?
• No transaction processing – end to
end automation is not optional
• Data is key for personalised care –
GBS will have a natural role in
managing this on behalf of the wider
organisation
• Humans will focus on disruption “N of 1” personalised care
Evolution of trusted patient / caregiver relationship
From care to health to wellbeing
Interconnected health communities
Affordable health for all
Personal cognitive & AI for improved outcomes
Health data ownership by consumers
Acceleration of digital health evolution
Regulation encouraging long-term accountability
Native data-oriented entrants disrupting incumbents
The Future of Health will change the demands placed on Life Sciences organisations and in turn GBS needs to be ready to adapt to support this
What does the Future of Health mean for GBS in 2040?
Life sciences and healthcare© 2019 Deloitte MCS Limited. All rights reserved.
How do you expect your organisation to change its use of Shared Services in the next 3–5 years?
Source: 2019 Deloitte Global Shared Services Survey
Life Sciences organisations have historically led the charge in innovation and digital initiatives in GBS but others are starting to play catch up
How does this compare to other industries?
4%5%
13%10%
13%15%
12%20%
13%15%
16%15%
19%15%
23%20%
15%30%
49%45%
46%65%
53%65%
32%40%
47%55%
48%65%
49%55%
50%45%
54%50%
54%75%
57%60%
68%55%
35%20%
40%25%
35%30%
0% 20% 40% 60% 80% 100%
# of processes outsourced
# of geographies/regions being served by SSCs
% of internal business units served by SSCs
# of processes delivered on a regional basis
# of processes delivered on a global basis
# of customer-facing processes in SSCs
# of transactional processes in SSCs
# of knowledge-based processes in SSCs/COEs
# of functions in shared services
Focus on digital experience
Focus on continuous improvement
Use of robotics
Life sciences respondents
Increase somewhat
Increase significantly
All respondents
Increase somewhat
Increase significantly
Life sciences and healthcare© 2019 Deloitte MCS Limited. All rights reserved.
Game-changing practices delivering transformational and sustainable value
Our point of view: game-changing practices in GBS
Cultivate tomorrow’s talent
6
Advance cross-functional structures
5
Disrupt leadership paradigms
1
Indoctrinate the brand and culture
2
Build a peer,Not a cost centre
3
Design for operating agility
7
Incite data-driven capabilities
10
Measure what matters, now
8
Lead the digital revolution
9
Set the toneStrong leadership with palpable objectives and organisational alignment
Run it like a business
4
Lay the foundationGovernance, structure and process design for an influential and flexible organisation
Unlock valueRadical transformation to drive value
This publication has been written in general terms and we recommend that you obtain professional advice before acting or refraining from action on any of the contents of this
publication. Deloitte MCS Limited accepts no liability for any loss occasioned to any person acting or refraining from action as a result of any material in this publication.
Deloitte MCS Limited is registered in England and Wales with registered number 03311052 and its registered office at Hill House, 1 Little New Street, London, EC4A 3TR, United
Kingdom.
Deloitte MCS Limited is a subsidiary of Deloitte LLP, which is the United Kingdom affiliate of Deloitte NWE LLP, a member firm of Deloitte Touche Tohmatsu Limited, a UK private
company limited by guarantee (“DTTL”). DTTL and each of its member firms are legally separate and independent entities. DTTL and Deloitte NWE LLP do not provide services to
clients. Please see www.deloitte.com/about to learn more about our global network of member firms.
© 2019 Deloitte MCS Limited. All rights reserved.